Inhibitors of glycoprotein processing alter T-cell proliferative responses to antigen and to interleukin 2.
Most of the cell-surface molecules involved in T-cell immune responses are N-linked glycoproteins. We have investigated the effects of inhibitors of glycoprotein processing on specific T-cell functions, with the dual aims of examining the functional role of carbohydrate and of testing the usefulness of such compounds as immunomodulators. Treatment of a cloned murine helper T-cell line with these inhibitors differentially affects the proliferative response of the cell, depending upon the nature of the stimulus. Treatment with the plant alkaloid swainsonine, which inhibits the processing mannosidase II and causes the accumulation of glycoproteins bearing hybrid-type oligosaccharide structures, enhances the proliferative response of the T-cell clone to antigen and to the mitogen concanavalin A. Treatment with another plant alkaloid, castanospermine, which inhibits glucosidase I and causes the accumulation of glucose-containing high-mannose structures, has the opposite effect and inhibits the proliferative response of the T cell to antigen. Cell-surface oligosaccharide alteration does not affect antigen recognition, as judged by the lack of effect of either drug on interleukin 2 production following antigen stimulation. Cells treated with either alkaloid proliferate poorly to exogenous interleukin 2 and may have defective interleukin 2 receptor function. Swainsonine-treated cells apparently have compensatory alterations that can overcome the reduced responsiveness to interleukin 2. Antibody-binding studies indicate that normal quantities of many cell-surface molecules, including the T-cell receptor for antigen, are expressed by the treated cells.
D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D002999:Clone Cells; D003208:Concanavalin A / Q000494:pharmacology; D004306:Dose-Response Relationship, Immunologic; D006023:Glycoproteins / Q000378:metabolism; D007212:Indolizines; D007376:Interleukin-2 / Q000096:biosynthesis / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects*; D008361:Mannosidases / Q000037:antagonists & inhibitors; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D017026:Swainsonine; D013601:T-Lymphocytes / Q000276:immunology*; D001617:beta-Glucosidase / Q000037:antagonists & inhibitors; D054836:Indolizidines
D000470:Alkaloids; D003208:Concanavalin A; D006023:Glycoproteins; D007212:Indolizines; D007376:Interleukin-2; D008361:Mannosidases; D017026:Swainsonine; D001617:beta-Glucosidase; C037806:castanospermine; D054836:Indolizidines